Nelfinavir plasma levels under twice-daily and three-times-daily regimens: High interpatient and low intrapatient variability

Therapeutic Drug Monitoring

Volumn 23, Issue 4, 2001, Pages 394-398

  Marzolini, Catia ^a   Buclin, Thierry ^a   Decosterd, Laurent Arthur ^a   Biollaz, J́rôme ^a   Telenti, Amalio ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Dosing regimen; Drug monitoring; Interpatient and intrapatient variability; Nelfinavir; Plasma concentration

Indexed keywords

NELFINAVIR; PROTEINASE INHIBITOR;

ADULT; AGE DISTRIBUTION; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG RESPONSE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PRIORITY JOURNAL; STEADY STATE;

ADULT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; NELFINAVIR;

EID: 0034896885     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200108000-00012     Document Type: Article

References (22)

1. HIV protease inhibitors
2. Protease inhibitors, resistance, cross-resistance, fitness and the choice of initial and salvage therapies
3. Current status and perspectives of the pharmacokinetics of antiretroviral drugs as an additional tool in the management of HIV/AIDS
4. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients
5. Drug monitoring of antiretroviral therapy for HIV-1 infection: Method validation and results of a pilot study
6. Therapeutic drug monitoring of antiretrovirals in human immunodeficiency virus infection
7. The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy
8. Therapeutic drug monitoring of nelfinavir in HIV patients with liver disease
9. Nelfinavir: An update on its use in HIV infection
10. Comparison of BID and TID Viracept in combination with stavudine (d4T) and lamivudine (3TC)
11. A comparison of the long-term antiviral efficacy of BID and TID dosing of nelfinavir in combination with stavudine (d4T) and lamivudine (3TC) up to 96 weeks
12. An open-label randomized trial switching nelfinavir dosing from TID to BID: twelve-month report
13. Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir, nelfinavir and the non-nucleoside reverse transcription inhibitor efavirenz by HPLC after solid-phase extraction
14. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection
15. Safety, pharmacokinetics, and antiretroviral activity of the potent, specific human immunodeficiency virus protease inhibitor nelfinavir: Results of a phase I/II trial and extended follow-up in patients infected with human immunodeficiency virus
16. Clinical pharmacokinetics of nelfinavir combined with efavirenz and stavudine during rescue treatment of heavily pretreated HIV-infected patients
17. Pharmacokinetic profile of nelfinavir (NFV) and efavirenz (EFV) in combination therapy administered to HIV-1 infected patients
18. Interoccasion variability of indinavir in HIV-infected patients
19. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1 infected patients
20. Sexual dysfunction with protease inhibitors